GB9812550D0 - Tumour therapy and imaging - Google Patents

Tumour therapy and imaging

Info

Publication number
GB9812550D0
GB9812550D0 GBGB9812550.3A GB9812550A GB9812550D0 GB 9812550 D0 GB9812550 D0 GB 9812550D0 GB 9812550 A GB9812550 A GB 9812550A GB 9812550 D0 GB9812550 D0 GB 9812550D0
Authority
GB
United Kingdom
Prior art keywords
imaging
tumour therapy
tumour
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9812550.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aepact Ltd
Original Assignee
Aepact Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aepact Ltd filed Critical Aepact Ltd
Priority to GBGB9812550.3A priority Critical patent/GB9812550D0/en
Publication of GB9812550D0 publication Critical patent/GB9812550D0/en
Priority to AU59469/99A priority patent/AU5946999A/en
Priority to PCT/GB1999/001870 priority patent/WO1999064065A2/en
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
GBGB9812550.3A 1998-06-11 1998-06-11 Tumour therapy and imaging Ceased GB9812550D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9812550.3A GB9812550D0 (en) 1998-06-11 1998-06-11 Tumour therapy and imaging
AU59469/99A AU5946999A (en) 1998-06-11 1999-06-11 Tumour therapy and imaging
PCT/GB1999/001870 WO1999064065A2 (en) 1998-06-11 1999-06-11 Tumour therapy and imaging

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9812550.3A GB9812550D0 (en) 1998-06-11 1998-06-11 Tumour therapy and imaging

Publications (1)

Publication Number Publication Date
GB9812550D0 true GB9812550D0 (en) 1998-08-05

Family

ID=10833545

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9812550.3A Ceased GB9812550D0 (en) 1998-06-11 1998-06-11 Tumour therapy and imaging

Country Status (3)

Country Link
AU (1) AU5946999A (en)
GB (1) GB9812550D0 (en)
WO (1) WO1999064065A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308363D0 (en) * 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
RU2744860C2 (en) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Antibodies and their conjugates
WO2018071435A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63219374A (en) * 1987-03-09 1988-09-13 Takara Shuzo Co Ltd Chemically modified carboxypeptidase and use thereof
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
CA2038935C (en) * 1989-08-07 1998-12-08 Luciana Sartore Biologically active drug polymer derivatives and method for preparing same
GB9624993D0 (en) * 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy

Also Published As

Publication number Publication date
WO1999064065A2 (en) 1999-12-16
WO1999064065A3 (en) 2000-06-29
AU5946999A (en) 1999-12-30

Similar Documents

Publication Publication Date Title
IL142729A0 (en) Method for improved imaging and photodynamic therapy
ZA979096B (en) Viral and cancer treatment
EP1056514A4 (en) Endoluminal implant with therapeutic and diagnostic capability
GB2339379B (en) Radiation therapy device
GB9811598D0 (en) Diagnosis and treatment of cancer
GB9816556D0 (en) Therapy
AU1710600A (en) Enhanced radiation therapy
IL123311A0 (en) Multi-frequency ultrasonic imaging and therapy
GB9812550D0 (en) Tumour therapy and imaging
GB9703633D0 (en) Cancer therapy
GB9819999D0 (en) Treatment of cancer
EP1112250A4 (en) Therapeutic compounds and methods
IL132531A0 (en) Detection and therapy of tumors
GB9421223D0 (en) Tissue imaging in gene therapy
IL136210A0 (en) Reagent for tumor therapy and/or imaging
GB9810920D0 (en) Therapeutic use
GB9804361D0 (en) Cancer treatment
GB0020261D0 (en) Therapeutic treatment
AU2918199A (en) Tumour imaging and therapeutic agents
GB9828564D0 (en) Materials and methods for the treatment and diagnosis of cancer
GB9811624D0 (en) Therapeutic use
GB9825610D0 (en) Combined rapid diagnosis and therapy
EP1150967A4 (en) Therapeutic compounds and methods
GB9716289D0 (en) Tumour treatment
GB9806039D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)